C-Met inhibitors

Anum Mughal; Hafiz Muhammad Aslam; Asfandyar Sheikh; Agha Muhammad Hammad Khan; Shafaq Saleem

doi:10.1186/1750-9378-8-13

C-Met inhibitors

Anum Mughal
, Hafiz Muhammad Aslam
, Asfandyar Sheikh
, Agha Muhammad Hammad Khan
, Shafaq Saleem

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.

Original language	English (US)
Article number	13
Journal	Infectious Agents and Cancer
Volume	8
Issue number	1
DOIs	https://doi.org/10.1186/1750-9378-8-13
Publication status	Published - 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer
Tyrosine kinase
c-Met

Access to Document

10.1186/1750-9378-8-13

Cite this

@article{8988126aa2ad43b9af48b5d0869f3c7d,

title = "C-Met inhibitors",

abstract = "c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.",

keywords = "Cancer, Tyrosine kinase, c-Met",

author = "Anum Mughal and Aslam, \{Hafiz Muhammad\} and Asfandyar Sheikh and Khan, \{Agha Muhammad Hammad\} and Shafaq Saleem",

year = "2013",

doi = "10.1186/1750-9378-8-13",

language = "English (US)",

volume = "8",

journal = "Infectious Agents and Cancer",

issn = "1750-9378",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - C-Met inhibitors

AU - Mughal, Anum

AU - Aslam, Hafiz Muhammad

AU - Sheikh, Asfandyar

AU - Khan, Agha Muhammad Hammad

AU - Saleem, Shafaq

PY - 2013

Y1 - 2013

N2 - c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.

AB - c-Met is a receptor tyrosine kinase that encodes protein such as hepatocyte growth factor receptor (HGFR). Inappropriate activity of c-Met can cause wide variety of carcinomas. c-Met inhibitor are relatively new class of small molecules that inhibit the enzymatic activity of c-Met tyrosine kinase. Met inhibitors divided into two main classes: class I (SU-11274-like) and class II (AM7-like). The use of c-Met inhibitors with other therapeutic agents could be crucial for overcoming potential resistance as well as for improving overall clinical benefit. Met pathway inhibitors might be used in combination with other treatments, including chemo-, radio- or immunotherapy.

KW - Cancer

KW - Tyrosine kinase

KW - c-Met

UR - https://www.scopus.com/pages/publications/84875860383

U2 - 10.1186/1750-9378-8-13

DO - 10.1186/1750-9378-8-13

M3 - Article

AN - SCOPUS:84875860383

SN - 1750-9378

VL - 8

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

IS - 1

M1 - 13

ER -

C-Met inhibitors

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this